Literature DB >> 31508188

LITHIUM-INDUCED NEPHROGENIC DIABETES INSIPIDUS RESPONSIVE TO DESMOPRESSIN.

E Şenocak Taşçi1, H Eralp1, K Kayataş1.   

Abstract

Nephrogenic diabetes insipidus (NDI) is the most common renal side effect seen with lithium therapy. Persisting cases after the cessation of the therapy may be seen when lithium therapy is continued for too long. Although desmopressin treatment is not one of the accepted treatment modalities for NDI, there are few reports using desmopressin treatment in unresponsive cases. Herein, we reported the fourth lithium-induced NDI case in the literature responsive to desmopressin therapy.

Entities:  

Keywords:  desmopressin; diabetes insipidus; lithium; nephrogenic

Year:  2019        PMID: 31508188      PMCID: PMC6711641          DOI: 10.4183/aeb.2019.270

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  9 in total

Review 1.  Lithium and the kidney: an updated review.

Authors:  M Gitlin
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings.

Authors:  Francesco Trepiccione; Birgitte Mønster Christensen
Journal:  J Nephrol       Date:  2010 Nov-Dec       Impact factor: 3.902

3.  Desmopressin and indomethacin therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate.

Authors:  R S Weinstock; A M Moses
Journal:  South Med J       Date:  1990-12       Impact factor: 0.954

4.  Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP.

Authors:  D S Stasior; D Kikeri; B Duel; J L Seifter
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

Review 5.  Nephrogenic diabetes insipidus persisting 57 months after cessation of lithium carbonate therapy: report of a case and review of the literature.

Authors:  A F Guirguis; H C Taylor
Journal:  Endocr Pract       Date:  2000 Jul-Aug       Impact factor: 3.443

Review 6.  Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy.

Authors:  R Boton; M Gaviria; D C Batlle
Journal:  Am J Kidney Dis       Date:  1987-11       Impact factor: 8.860

7.  Nephrogenic diabetes insipidus partially responsive to oral desmopressin in a subject with lithium-induced multiple endocrinopathy.

Authors:  C Kamath; J Govindan; A D Premawardhana; S J Wood; M A Adlan; L D Premawardhana
Journal:  Clin Med (Lond)       Date:  2013-08       Impact factor: 2.659

Review 8.  Diabetes Insipidus.

Authors:  H A Jenny Lu
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

9.  Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.

Authors:  D Marples; S Christensen; E I Christensen; P D Ottosen; S Nielsen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.